BIOMARIN PHARMACEUTICAL INC's ticker is and the CUSIP is 09061GAH4. A total of 63 filers reported holding BIOMARIN PHARMACEUTICAL INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $405,000 | -5.6% | 400,000 | 0.0% | 0.00% | – |
| Q4 2020 | $429,000 | +2.1% | 400,000 | 0.0% | 0.00% | – |
| Q3 2020 | $420,000 | -14.1% | 400,000 | 0.0% | 0.00% | -100.0% |
| Q2 2020 | $489,000 | +16.7% | 400,000 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $419,000 | -0.9% | 400,000 | 0.0% | 0.00% | – |
| Q4 2019 | $423,000 | +7.6% | 400,000 | 0.0% | 0.00% | -100.0% |
| Q3 2019 | $393,000 | -5.3% | 400,000 | 0.0% | 0.00% | – |
| Q2 2019 | $415,000 | -88.4% | 400,000 | -88.5% | 0.00% | -100.0% |
| Q1 2019 | $3,567,000 | +6.4% | 3,487,000 | +3.5% | 0.01% | +66.7% |
| Q4 2018 | $3,351,000 | -15.1% | 3,370,000 | -9.1% | 0.00% | -40.0% |
| Q3 2018 | $3,949,000 | -2.6% | 3,706,000 | -7.7% | 0.01% | -16.7% |
| Q2 2018 | $4,056,000 | -65.4% | 4,015,000 | -67.9% | 0.01% | -68.4% |
| Q1 2018 | $11,736,000 | -2.0% | 12,501,000 | +4.0% | 0.02% | +5.6% |
| Q4 2017 | $11,975,000 | +47.7% | 12,020,000 | +50.2% | 0.02% | -30.8% |
| Q3 2017 | $8,105,000 | – | 8,000,000 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Wellesley Asset Management | 53,670 | $57,726,000 | 3.34% |
| SHENKMAN CAPITAL MANAGEMENT INC | 26,959,000 | $29,149,000 | 3.04% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 84,134,000 | $90,539,000 | 1.93% |
| Cheyne Capital Management (UK) LLP | 3,220,000 | $3,452,000 | 1.75% |
| PFM Health Sciences, LP | 40,300,000 | $43,210,000 | 1.52% |
| Sonora Investment Management, LLC | 6,370,000 | $6,807,000 | 0.56% |
| MACKAY SHIELDS LLC | 66,018,000 | $70,980,000 | 0.49% |
| ZAZOVE ASSOCIATES LLC | 1,500,000 | $1,608,000 | 0.20% |
| IRON Financial LLC | 275,000 | $295,000 | 0.15% |
| PALISADE CAPITAL MANAGEMENT, LP | 3,000,000 | $3,216,000 | 0.08% |